|
|
|
|
|
Detail |
| hsa-miR-223 |
|
Unspecified |
WITHDRAWN:MicroRNA profile in peripheral blood T cells of patients with primary biliary cirrhosis. |
2008 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Distinctive patterns of microRNA expression in primary muscular disorders. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Causal |
MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Micro-RNA profiling in kidney and bladder cancers. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
A microRNA expression signature of human solid tumors defines cancer gene targets. |
2006 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. |
2005 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Causal |
Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Causal |
Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. |
2008 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. |
2008 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Causal |
Emerging role for microRNAs in acute promyelocytic leukemia. |
2007 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Causal |
Potential role of miR-9 and miR-223 in recurrent ovarian cancer. |
2008 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Karyotype specific microRNA signature in chronic lymphocytic leukemia. |
2009 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival |
2009 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia |
2009 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia |
2009 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls |
2009 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Causal |
MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. |
2008 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. |
2008 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
MicroRNA-regulated pathways associated with endometriosis. |
2009 |
|
|
|
|
|
|
| hsa-miR-223 |
|
Unspecified |
MicroRNA-29c and microRNA-223 downregulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. |
2009 |
|
|
|
|
|
|